TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a first-person report published by Being Patient on October 6, 2026, Ron Carr describes three health notifications that changed how he viewed Alzheimer’s risk and prevention. The supplied excerpt details learning he carries two APOE4 copies and discovering coronary artery plaque on a scan; it does not include the third notification or establish that any intervention prevents Alzheimer’s disease.
Being Patient published a first-person account by patient advocate Ron Carr on October 6, 2026, describing how learning he carries two copies of APOE4 and later finding coronary artery plaque changed his view of Alzheimer’s risk and prevention. Carr presents the tests as personal turning points, not as proof that he will develop Alzheimer’s disease or that any particular lifestyle change will prevent it.
Carr says he received the genetic result about two years before writing the account. Research into Alzheimer’s risk also explores possible links between gut-produced molecules and the disease. He initially treated ordinary lapses, such as forgetting a name or misplacing keys, as possible signs of disease. He describes changing diets, adding supplements and altering his exercise routine while trying to find ways to affect his future risk. He also says prescription sleeping pills left him groggy and irritable, and that the uncertainty put strain on his daily life.
Over time, Carr says, he came to understand that an APOE4 result is a risk factor, not a diagnosis. He describes turning to research and resources, including the USC Center for Personalized Brain Health and Being Patient, to learn about risk factors that might be modifiable. His account does not report that he has been diagnosed with Alzheimer’s disease.
A separate health notification came after a clinician at USC recommended a coronary artery calcium scan in light of Carr’s APOE4 status and cardiovascular concerns. Carr says the scan showed significant calcified plaque, concentrated mainly in the left anterior descending artery. He reports that clinicians then lowered his LDL cholesterol and ApoB targets and used medication. He says follow-up testing showed no structural heart damage. The supplied source excerpt ends during his discussion of this second notification and does not provide details of the third.
How Risk Results Changed Carr’s Choices
Carr’s account illustrates how a genetic finding can influence health decisions even when it does not predict an individual outcome. He describes moving from fear and close monitoring of everyday memory to a more measured understanding of risk. That distinction matters to readers considering genetic testing: a result can inform a discussion with a clinician, but it is not itself a diagnosis or a certain forecast.
The heart scan also changed Carr’s understanding of prevention. He says he felt healthy and had previously believed his cholesterol was acceptable, yet imaging identified coronary plaque. His story shows how a test may uncover a separate condition and prompt changes in care. It does not show that APOE4 caused his plaque, or that heart treatment will prevent Alzheimer’s disease.
For readers, the main takeaway is the value of interpreting test results with qualified health professionals rather than reacting to them alone. Carr’s reported dietary experiments and supplement use are personal choices, not evidence-based instructions for others. The account offers perspective on uncertainty and decision-making, not medical advice.
genetic testing kit for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Genetic Result to Heart Scan
Carr identifies himself as a retired local government executive and patient advocate focused on Alzheimer’s prevention, genetic testing and cardiovascular health. He says he has shared his perspective through the USC Center for Personalized Brain Health and the Family Heart Foundation, where he serves as an ambassador.
In the account, Carr connects his interest in cardiovascular health to his father’s heart attack at age 65. He says he ran regularly, changed his diet and eventually accepted statin treatment, while believing his cholesterol was at an acceptable level. The calcium scan, performed after discussion with his clinician, changed that assessment by showing calcified plaque. Carr describes the finding as a diagnosis of atherosclerotic cardiovascular disease at age 65.
The article refers to a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That is a population-level estimate reported in Carr’s account; it does not establish that an individual can avoid dementia through specific changes. The source excerpt provides no details about the third notification named in the headline.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in his Being Patient account
As an affiliate, we earn on qualifying purchases.
The Third Notification Is Missing
The supplied source material describes two notifications in detail, although the headline promises three. It ends as Carr begins discussing conversations with people close to him, so the third notification, its timing and its findings cannot be established from the excerpt. No details about it should be inferred.
The excerpt also does not specify the scan’s calcium score, the exact LDL or ApoB targets, the medications used, or the duration of follow-up. It gives no evidence that Carr has Alzheimer’s disease, and it does not establish that his genetic result caused his heart condition. The account is personal reporting, not a controlled study of dementia prevention.
LDL cholesterol lowering medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Full Account Could Clarify
The next step for readers seeking the complete story is to consult the full Being Patient report, which may contain the third notification and details absent from the supplied excerpt. Until those details are available, the third event and any conclusions Carr draws from it remain unconfirmed here.
For people weighing genetic or cardiovascular testing, Carr’s account points to questions for a clinician: what a result can and cannot tell them, whether follow-up testing is appropriate, and how a finding affects their individual care. Any decisions about medication, supplements, diet or testing should be made with a qualified health professional. The report does not establish a specific Alzheimer’s prevention plan for readers.
As an affiliate, we earn on qualifying purchases.
Key Questions
What two health notifications does the supplied account describe?
Carr says he learned he carries two copies of APOE4, then received a coronary artery calcium scan showing significant calcified plaque, mainly in the left anterior descending artery.
Does carrying two APOE4 copies mean someone will develop Alzheimer’s?
No. Carr’s account describes APOE4 as a risk factor, not a diagnosis. The excerpt does not say that he has Alzheimer’s disease or that his future outcome is certain.
What does the source say about the third notification?
The supplied excerpt does not describe it. Although the headline refers to three notifications, the text provided here details only two and ends before completing Carr’s account.
Does Carr’s story show that his health changes prevent dementia?
No. It reports his personal experience and decisions, but does not establish that his diet, exercise, supplements, or cardiovascular treatment prevent Alzheimer’s disease. Readers should discuss individual medical decisions with a qualified professional.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
